Evaluation of the Active Sentry System During Cataract Surgery With the Centurion Phacoemulsifier
SASCA
Observational Multicenter Registry to Assess the Enefits of Active Sentry Handpiece During Cataract Surgery With the Centurion Phacoemulsifier (SASCA)
2 other identifiers
observational
5,000
1 country
1
Brief Summary
Each new generation of phacoemulsification system has aimed to optimize the control of fluidics and the delivery of energy during phacoemulsification. Nicoli CM et al., (J Cataract Refract Surg 2016;42:157-162) suggested a better anterior chamber stability when using an active fluidics system. Malik PK et al., (Eye and Vision 2017;4:22) showed that using an IOP based phacoemulsification system in association with the use of an Intrepid balanced tip provides a reduction in CDE (Cumulated Dissipated Energy and EFU (Estimated Fluid Usage). It has also been shown that a lower CDE provides obvious benefits: less endothelium cells damages and lower complication rates (Mady MA et al., Clin.Ophthalmol. 2012; 6:503-10). The latest technologies, i.e. the Active Sentry Handpiece and Hybrid tips, have been introduced to further improve the safety of phacoemulsification. The Active Sentry system has moved pressure sensors closer to the operated eye, hence further reducing the risk of surge during procedures. (Thorne A et al. Phacoemulsifier occlusion break surge volume reduction, J Cataract Refract Surg. 2018;44:1491-1496). The Hybrid tips have been designed to prevent posterior capsule rupture in the event of contact with the capsule. This new technology allows phacoemulsification procedures under reduced infusion pressures and a "high-vacuum - low energy" strategy which may lead to a safer procedure. Data from this study will try to demonstrate that cataract surgeries with Active Sentry will need less CDE and therefore may be safer, due to the surge effects decrease. This CDE parameter will be analysed according to differents subgroups: Presence of hybrid tip or balanced tip, cataract score based on the WHO nuclear grading recommendation (Thylefors B et al., (2002) The WHO Cataract Grading Group, Ophthalmic Epidemiology, 9:2, 83-95) The recent experiences conducted in real world condition in different sites have suggested that Centurion with AS was able to improved settings: maximum vacuum and UltraSound (US) time reduction and as a consequence a 20 to 30% CDE reduction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 29, 2021
CompletedFirst Posted
Study publicly available on registry
February 1, 2021
CompletedStudy Start
First participant enrolled
May 5, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 3, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 3, 2022
CompletedJanuary 15, 2026
January 1, 2026
10 months
January 29, 2021
January 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mean CDE (Cumulated Dissipated Energy)
Mean CDE measured by the phacoemulsifier in different groups according to baseline patients and/or eyes characteristics (nuclear cataract grading etc...)
The day of the cataract procedure
Secondary Outcomes (5)
Mean total procedure duration
The day of the cataract procedure
Mean total Ultrasound time (US time)
The day of the procedure
Mean procedure settings
The day of the procedure
Mean BSS volume
The day of the procedure
Frequency of adverse events
The day of the procedure
Study Arms (2)
Active sentry
Cataract procedures conducted with the active Sentry handpiece
Non-active sentry
Cataract procedures conducted with an handpiece different from the Active Sentry Handpiece
Eligibility Criteria
Patients who will undergo a cataract surgery in routine
You may qualify if:
- All consecutive patients undergoing unilateral or bilateral cataract surgery with the Centurion phacoemulsifier, with the ability to give informed consent.
- Patients will undergo the cataract surgery with or without the Active Sentry module and with or without hybrid tip according to centers practice.
- Patients will undergo a cataract scoring (nuclear grade 1 to 3) prior surgery as described in the WHO recommendation:
You may not qualify if:
- Patients with :
- pupil dilation \<5mm
- zonular defects
- corneal opacities
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ophtalmopôle, Hôpital Cochin
Paris, Île-de-France Region, 75014, France
Related Publications (1)
Brezin AP, Monnet D, Lignereux F, Rozot P, Jilet L, Abdoul H. Impact of a handpiece with a built-in fluidics pressure sensor on phacoemulsification: a multicentre prospective comparative study. BMJ Open Ophthalmol. 2023 Nov;8(1):e001431. doi: 10.1136/bmjophth-2023-001431.
PMID: 37973548RESULT
Study Officials
- PRINCIPAL INVESTIGATOR
Antoine BREZIN, PhD & MD
Hopital Cochin, Ophthalmology, Paris
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 29, 2021
First Posted
February 1, 2021
Study Start
May 5, 2021
Primary Completion
March 3, 2022
Study Completion
March 3, 2022
Last Updated
January 15, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share